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An in vivo model has been established to study the role of macrophages in the initiation of angiogenesis by human breast tumour
spheroids in vivo. The extent of the angiogenic response induced by T47D spheroids implanted into the dorsal skinfold chamber in
nude mice was measured in vivo and compared to that induced by spheroids infiltrated with human macrophages prior to
implantation. Our results indicate that the presence of macrophages in spheroids resulted in at least a three-fold upregulation in the
release of vascular endothelial growth factor (VEGF) in vitro when compared with spheroids composed only of tumour cells. The
angiogenic response measured around the spheroids, 3 days after in vivo implantation, was significantly greater in the spheroids
infiltrated with macrophages. The number of vessels increased (macrophages vs no macrophages 3471.9 vs 2672.5, Po0.01), were
shorter in length (macrophages vs no macrophages 11674.92 vs 13676.52, Po0.008) with an increased number of junctions
(macrophages vs no macrophages 1470.93 vs 1171.25, Po0.025) all parameters indicative of new vessel formation. This is the first
study to demonstrate a role for macrophages in the initiation of tumour angiogenesis in vivo.
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Angiogenesis, the development of new blood vessels from an
existing vascular network, is a prerequisite for tumour growth
beyond 2 mm in diameter, as it ensures the adequate supply of
oxygen and nutrients for tumour cell expansion and spread
(Folkman, 1971; Skobe et al, 1997). Blood vessels grow rapidly in
tumours, are usually disorganised, often incomplete, lacking in
structural integrity and prone to collapse, resulting in areas of
inadequate perfusion and transient hypoxia (low oxygen tension;
Blood and Zetter, 1990). Hypoxia has recently been shown to be an
important stimulus for angiogenesis, promoting tumour and
stromal cell secretion of such potent proangiogenic growth factors
as vascular endothelial growth factor (VEGF; Bicknell et al, 1997).
VEGF then stimulates the rapid growth of new blood vessels
into hypoxic tumour areas, which results in their subsequent
reoxygenation.
Tumour associated macrophages (TAMs) are widespread in
human breast carcinomas (Kelly et al, 1988; Volodko et al, 1998;
Lin et al, 2001; Bingle et al, 2002a) and it has been suggested that
they may play an important role in the regulation of tumour
angiogenesis. In vitro studies have shown that TAMs secrete
growth factors that are mitogenic for both tumour cells and
endothelial cells, in addition to stimulating the activity of a
number of proteolytic enzymes in breast cancer (O’Sullivan et al,
1993; Pyke et al, 1993; Lewis et al, 1995; Lewis et al, 2000). We
and others have demonstrated that breast tumours containing
increased numbers of macrophages are significantly more vascu-
larised and have greater axillary lymph node involvement than
tumours with low numbers of macrophages (Leek et al, 1996,
1997). This could explain, at least in part, the finding that high
focal TAM infiltration in primary human breast tumours is
associated with reduced relapse-free and overall survival. (Leek
et al, 1996; Volodko et al, 1998). A similar positive correlation
between macrophage infiltration and angiogenesis has also been
reported for ovarian tumours (Orre and Rogers, 1999) and B-cell
non-Hodgkin’s lymphomas (Vacca et al, 1999). Specific accumula-
tion of macrophages expressing VEGF is seen in avascular, hypoxic
areas of human breast tumours, whereas in highly vascularised,
well-oxygenated areas of the same tumour, macrophages are
present but VEGF is not expressed (Lewis et al, 2000). This
suggests that hypoxia stimulates VEGF release from macrophages
in tumours, and is supported by the finding that macrophages
release VEGF in response to hypoxia in vitro (Harmey et al, 1998).
Thus, once macrophages are located within the hypoxia/necrotic
regions of the tumour, they may promote tumour progression by
releasing VEGF and potentially other proangiogenic cytokines and
enzymes, which stimulate tumour angiogenesis.
The mouse dorsal skinfold chamber model allows direct in situ
visualisation and monitoring of implanted tumour spheroids and
the surrounding blood vessels in vivo (Torres-Filho et al, 1995;
Borgstrom et al, 1998; Bingle et al, 2002b; Nilsson et al, 2002).
Implantation of the chamber with human breast tumour cells
or spheroids permits accurate, serial, noninvasive monitoring
of tumour growth, and angiogenesis using in vivo micro-
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scopy, facilitating accurate spatial and temporal quantification
(Borgstrom et al, 1998; Gilead et al, 2004). Using this model, the
requirement of VEGF for tumour angiogenesis and maintenance of
vessel integrity has been demonstrated (Borgstrom et al, 1996;
Lichtenbeld et al, 1998). Inhibition of endogenous VEGF results in
decreased microvessel density and microvascular regression in a
similar model (Jain et al, 1998). Moreover studies, investigating the
immediate events which follow the initiation of tumour angio-
genesis, provide evidence that new functional vessels form when
the tumour mass consists of only 100– 300 tumour cells (Li et al,
2000). Administration of ex-flk1 (a soluble, truncated VEGF
receptor protein) resulted in partial inhibition of the early
angiogenic and tumour growth activities suggesting that tumour
growth is delayed prior to the onset of angiogenesis (Li et al, 2000).
Despite the increasing body of evidence, both experimental and
clinical, implicating macrophages in breast tumour angiogenesis,
there have been no reports of in vivo studies to demonstrate
unequivocally their proangiogenic activity in tumours. The current
study was designed to determine the role of macrophages in
the initiation of tumour angiogenesis, by isolating the tumour
spheroid from host (murine) cells. Human breast tumour
spheroids were infiltrated with human monocytes in vitro, coated
with alginate and implanted into dorsal skinfold chambers on
nude mice. The resultant angiogenesis surrounding the spheroids
was quantified using image analysis, and compared with spheroids
consisting of tumour cells alone.
MATERIALS AND METHODS
Isolation of human monocytes
Peripheral blood mononuclear cells were isolated from normal
healthy volunteers with Local Ethics Committee approval, LREC 02/
303. Blood was collected into sodium citrate (final volume 10%)
tubes and after centrifugation serum was collected and CaCl2 added
to make platelet rich plasma-derived serum (PRPDS). The blood
cells were layered onto a Ficoll gradient (Amersham Biosciences)
and after centrifugation the mononuclear cell layer collected. The
cells were further purified using CD14 magnetic beads according to
the manufacturers instructions (Miltenyi Biotec). Briefly, the cells
were incubated with the labelled beads at 41C for 20–30 min,
washed in ice-cold PBSþ 0.5% BSA, 2 mM EDTA, and separated
from unlabelled cells using a magnetic column.
Human breast tumour spheroids
96-well tissue culture plates (Corning) were coated with 100 ml of
1.5% high-gel point agarose per well. The human T47D breast
tumour cell line was subcultured and 104 cells plated per well in
200ml culture medium consisting of RPMI (Sigma), 10% foetal calf
serum FCS, (Sigma), 100 U ml1 penicillin (Gibco), 100 mg ml1
streptomycin (Gibco) and 2 mM glutamine (Gibco). The plates were
incubated at 371C, 5% CO2 for 4 days, thereafter the culture
medium was changed on alternate days by replacing 100 ml of
medium with 100 ml fresh culture medium. Preliminary studies
have established that between 20–24 days in culture the spheroids
are approximately 600–800mm in diameter and have a necrotic
core (unpublished results).
Tumour spheroid coating
Preliminary studies were carried out to determine the optimum
conditions for monocyte infiltration and alginate coating of the
spheroids, including the assessment of VEGF and bFGF release
from infiltrated and noninfiltrated spheroids. The spheroids were
prepared for in vivo implantation using the following protocol.
Spheroids were cultured for 14– 18 days and human monocytes
(105 spheroid1 well1) were added and allowed to infiltrate the
spheroids for 24 h. In order to prevent autologous (i.e. murine)
macrophages from infiltrating the spheroid following implantation
in vivo, the spheroids were coated with alginate (Read et al, 1999,
2001) by immersion in a 1.25% solution of sodium alginate
(Pronova, UK) and transfer to a 0.1 M CaCl2 solution, prepared
from a 0.15 M NaCl stock solution, to initiate gel-formation by
cross-linking. The alginate coated spheroids were washed three
times with PBS and once in RPMI with 10% FCS (Read et al, 1999,
2001). The coated spheroids were cultured for a further 5 days to
allow differentiation of monocytes to macrophages. Control
spheroids without monocytes were also coated with alginate and
cultured in an identical manner. Monocytes alone do not form
spheroids. In order to demonstrate the diffusion of macro-
molecules through the alginate, Hoescht 33258 (Molecular Probes)
was added to the culture medium for 15 min at various timepoints
up to 24 days, to allow assessment of spheroid viability and
porosity over the in vivo time course. Spheroids were examined
using a fluorescent microscope.
Assessment of monocyte infiltration into spheroids
T47D spheroids were established in culture and allowed to grow for
17 days before purified monocytes (105) were added to the culture
in RPMI with 5% PRPDS, penicillin (100 U ml1), streptomycin
(100 mg ml1) and glutamine (2 mM). The spheroids were collected
on days 1, 4, and 7 after monocyte addition, formalin-fixed and
embedded in paraffin. Sections were stained with anti-human CD68
(Dako, see below for immunohistochemistry details) a specific
monocyte/macrophage marker, and the number of monocytes/
macrophages in each spheroid section counted. For each time point
at least five different spheroids and three sections from each
spheroid were used to quantify the number of macrophages present.
VEGF and bFGF quantification
The release of VEGF and bFGF critical regulators of tumour
angiogenesis, were determined from spheroids both in the
presence and absence of human macrophages. Culture medium
was collected at various time points, before and after the addition
of monocytes (days 14 –18) to spheroid cultures, before and after
alginate coating (days 15–19) and immediately before spheroid
implantation into the skinfold chamber model (days 21–24). At all
times, control spheroids (no monocyte infiltration) were cultured
in parallel and medium was collected simultaneously. Immediately
after collection, the medium was centrifuged to remove cell debris
and stored in aliquots at 201C until assayed. The ELISAs were
performed using commercially available kits (R&D Systems) and
carried out according to the manufacturers protocol.
Histology and immunohistochemistry
Spheroids (with and without monocytes) were collected directly
into buffered formalin, processed, paraffin –embedded, and cut
into 5 mm sections. The sections were dewaxed in xylene and
absolute alcohol before endogenous peroxide was blocked with
hydrogen peroxide. Antigen retrieval was achieved by incubating
in protease type XXIV (Sigma) at 371C for 20 min. After incubation
in normal serum, anti-CD68 (Dako) was diluted 1 : 100 in PBS
added to sections and incubated overnight at 41C. A Vectastain kit
(Vector Laboratories) was used for secondary antibody application
and detection. Spheroids that had been implanted in the dorsal
skinfold chamber were collected at the end of each experiment and
fixed immediately in zinc chloride saline (Beckstead, 1994),
processed and embedded in paraffin wax. Sections were cut as
described previously, stained with haematoxylin and eosin and
examined to determine the exact location of the spheroid.
Appropriate other sections were stained for CD 68, (macrophages)
Hypoxia inducible Factor-1a (HIF-1a, Abcam) and with anti-
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platelet cell adhesion molecule antibody (endothelial cells, anti-
PECAM, CD-31, Abcam).
Animals and dorsal skinfold chamber model
Adult, male MF-1 nude mice (20–30 g, n¼ 10) were obtained from
the University of Sheffield Field Laboratories and were allowed food
and water ad libitum. All procedures were performed in accordance
with UK legislation under Home Office Project Licence PPL 40/2343.
The dorsal skinfold chamber manufactured from titanium
(Medical Workshops, University of Sheffield) was implanted into
the animal under hypnorm/diazepam anaesthesia (1 : 1,
0.1 ml 100 g1). The mice were placed on a heated pad, and a
double layer of skin extended perpendicular to the dorsum. A
circular area of skin and tissue was removed from one side to
expose a single layer of striated muscle, which was then
sandwiched between two symmetrical titanium frames. The
tumour spheroid (approximately 600mm) was placed in close
proximity to a blood vessel immediately before sealing the
chamber with a glass cover slip (Lehr et al, 1993; Bingle et al,
2002b; Nilsson et al 2002). Angiogenesis (around spheroids and at
sites within the chamber but distant to the spheroid), and
associated microcirculatory variables, including vessel length,
vessel number and junction numbers, were characterised using
in vivo microscopy. Visualisation of tumour spheroid growth and
angiogenesis in situ involved placing the mice in a plexiglass
restrainer. Mice were trained to sit in the restrainer prior to
surgery avoiding the need for anaesthesia and minimising any
effects of stress on microvasculature function. The restrainer was
fixed to the stage of a horizontally modified Nikon Optiphot
microscope. The window of the chamber protruded through a
longitudinal slot allowing the animal to sit in their normal position
and the tumour and associated microcirculation to be viewed.
Images of the preparation were monitored using a CCD camera
(Hitachi, UK), displayed on a monitor (Sony PVM-1443, UK) and
recorded on video (Sony S-VHS, UK) tape for off-line compu-
terised analysis (Angiosys, UK). The day of surgery was designated
day 0 and recordings were made on days 3 and 7.
At the end of the experiment the animals were killed and
appropriate tissue fixed in a zinc chloride fixative before paraffin
embedding, to determine the presence of macrophages in the
spheroids, as previously described.
Microvascular parameter analysis
The image analysis programme Angiosys (TCS, UK) was used to
assess new vessel formation. The area immediately surrounding
the spheroid and at least three randomly selected sites, distant to
the spheroid, were analysed. The two groups (five animals per
group) were analysed at 3 and 7 days after implantation of the
spheroid; the parameters measured were mean vessel length (mm),
an increase indicating endothelial proliferation and differentiation,
the total number of vessels per unit area (vessel density) with and
without blood flow indicating the new structures are functional
and the number of junctions (branch points) indicates vascular
network complexity. All images were collected for analysis using a
10 objective and the same area was measured at each time point
and for each animal. A formal assessment of blood flow was not
made. As the spheroids implanted in this series of experiments
were coated with alginate it was not possible to measure the growth
of new blood vessels into each spheroid.
Statistical analysis
Differences between groups was analysed using the Mann–
Whitney U test for nonparametric data. P-values o0.05 were
considered as significant.
RESULTS
Monocyte infiltration of spheroids in vitro
T47D breast tumour spheroids were cultured on agarose for 15– 18
days reaching approximately 600–800 mm in diameter, (Figure 1A)
with a hypoxic centre (Figure 1B and C) and therefore more closely
mimicked a small avascular breast tumour or micrometastatic
Figure 1 T47D spheroids cocultured with macrophages, sampled immediately before implantation and stained with (A) anti-CD68 antibody (brown
staining, arrows; N¼ necrotic core) (B) HIF antibody (red staining, arrows; N¼ necrotic core) and (C) negative control. (D) T47D spheroid coated with
alginate and cultured for 21 days before staining with Hoescht 33258. Under fluorescent light nuclei stain blue with this dye. (E) T47D spheroid collected
after implantation in dorsal skinfold chamber, chamber for 7 days and stained with haematoxylin and eosin. Alginate used to coat the spheroid is clearly
visible (arrows). (F) T47D spheroid collected in an identical manner to (E) but stained with anti-CD68 antibody to illustrate the continuing presence of
human macrophages (brown staining).
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deposit. Monocytes moved into these spheroids relatively quickly,
presumably attracted by various chemokines released from the
tumour cells. The total number of monocytes that migrated into
each spheroid was calculated at various time points after the
initiation of coculture in order to determine the rate of infiltration
(Figure 1A, Table 1). Monocyte migration into each spheroid
continued to increase with time from 432733.9 after 24 h to
1083711.9 after 7 days.
The amount of VEGF released from the spheroids was measured
by ELISA, and increased over the 7 days, with spheroids containing
monocytes releasing at least three times more VEGF than those
without monocytes (900–2000pg ml1 with monocytes and 220–
590pg ml1 without monocytes, Table 1). An ELISA was also used
to quantify bFGF release from the spheroids; however, no bFGF
was detected using this method.
The major aim of this study was to investigate whether
macrophages were involved in the initiation of tumour angio-
genesis and thus it was necessary to isolate the tumour spheroids
containing human macrophages from infiltration by mouse
macrophages, which would have made data interpretation difficult.
During the course of this study it was determined that the
optimum method for coating spheroids, which allowed implanta-
tion into the chamber without causing damage to the spheroid, was
to coculture a 14–16 day spheroid with monocytes for 24 h
followed by alginate coating. The coated spheroids were cultured
for a further 5 days before implantation, allowing macrophage
differentiation to occur. Alginate coating the spheroids at this
early time point resulted in suboptimal numbers of monocytes
infiltrating the spheroid. However, further measurements of
VEGF production at a time point immediately before implanta-
tion, from both infiltrated and noninfiltrated coated spheroids
indicated that the macrophage-containing spheroids were releas-
ing significantly more VEGF than the control spheroids (macro-
phages vs no macrophages 6807238 vs 226775pg ml1). Thus
macrophages within the alginate-coated spheroid were releasing
VEGF and therefore the contribution to the initiation of tumour
angiogenesis could be estimated in the in vivo model. A
homogeneous distribution of macrophages surrounding the
hypoxic centre was observed in the majority of spheroid sections
assessed. Three sections from five different spheroids were
quantified and used to estimate the number of infiltrated
macrophages per spheroid, which were approximately 400
macrophages (Table 1) at day 7.
In order to demonstrate the porosity of alginate to essential
nutrients and growth factors, coated spheroids were incubated
with Hoechst 33258 for 15 min, at days 10, 15, 20, and 24.
Fluorescent microscopy demonstrated that at all timepoints
(Figure 1D) the dye diffused across the alginate coating and
stained the tumour cell nuclei.
Angiogenesis in vivo
The dorsal skinfold chamber was surgically implanted into nude
mice, the tumour spheroids placed in the window in close
proximity to a vessel at the end of surgery and covered with a
glass coverslip (Figure 2). In vivo microscopy was performed on
days 3 and 7 post-surgery as it is generally accepted that
recordings cannot be made at earlier time points ensuring recovery
of the surgical site from any trauma. A typical H&E stained section
of a spheroid resected from the chamber at the end of an
experiment, with the alginate coating clearly visible, is represented
in Figure 1E. Sections were also stained for CD68 to ensure the
macrophages were still present but the number of macrophages in
each spheroid was not assessed at this time (Figure 1F). The
sections were also stained with F480, a specific marker of murine
macrophages, but no positive staining was detected (data not
shown).
The data collected from off-line analysis indicates that
angiogenesis were stimulated by the breast tumour spheroids in
the presence or absence of macrophages (Figure 3) but the
stimulus was increased in the early phase of angiogenesis (day 3) if
macrophages were present. Although the data showed that breast
tumour spheroids stimulated angiogenesis in the absence of
macrophages it also showed that the stimulus was greater in the
early phase of tumour angiogenesis if macrophages were present
(Figure 3). There was a significant difference between those
spheroids which had been infiltrated with human macrophages, for
all parameters measured on day 3; increased vessel number
Po0.011, increased number of junctions Po0.025 and shorter
mean vessel length Po0.046 all indicating increased angiogenesis
in the presence of macrophages. By day 7 the number of vessels
was significantly greater than on day 3 (49.573.08 and 3471.95
Table 1 The number of monocytes/macrophages infiltrating the spheroids was assessed by counting CD-68 positive cells present in representative
sections
Spheroids with macrophages Spheroids without macrophages
Day 14 Day 18 Day 21 Day 14 Day 18 Day 21
Number 432734 667739 1083712
VEGF (pg/ml) 900751* 1350785* 20007123* 220715.3 450725.2 590726.7
The spheroids were sampled at the time points indicated. VEGF (pg/ml) secreted by the uncoated spheroids in the presence and absence of monocyte macrophages is
presented. All data are presented as mean7s.e.m. and *denotes statistical significance P40.05 compared to control.
Figure 2 A representative photograph of the dorsal skinfold chamber
implanted on a nude mouse, taken immediately after surgery. This illustrates
how the chamber was attached to the animal and the lack of trauma to the
tissue under examination.
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Po0.001 with macrophages, 4673.29 and 2672.47 Po0.001
without macrophages) as was the number of junctions (2171.46
and 1470.93 Po0.001 with macrophages, 1671.47 and 1171.25
Po0.002 without macrophages) implying that new vessels had
branched from existing vessels. The mean tubule length measured
at these times was less on day 7 than on day 3 (95.273.58 and
11674.92 Po0.001 with macrophages, 102.275.58 and 13676.52
Po0.002 without macrophages) indicating that new shorter blood
vessels had sprouted due to the stimulatory effects of the tumour
spheroid. However, by day 7 the differences between spheroids
with and without macrophages were no longer significant.
(Figure 3) A formal assessment of blood flow velocity was not
made but the video recordings indicated that the vessels measured
were functional.
DISCUSSION
This is the first study to demonstrate that macrophages may
modulate tumour angiogenesis in the early stages of development,
with increased number of vessels and branches. A number of
studies have shown that macrophages congregate in large numbers
in the hypoxic areas of many solid tumours, which may be due to
the influence of hypoxia on the chemoattractant signalling cascade
in the tumour microenvironment ((Negus et al, 1997; Ueno et al,
2000, Grimshaw and Balkwill 2001). Macrophages have the ability
to both positively and negatively regulate tumour growth
(Mantovani et al, 1992); tumour cell cytostasis may be induced,
but in contrast tumour cell survival may be promoted by
macrophage activation and release of angiogenic and mitogenic
cytokines in the tumour microenvironment, such as VEGF
(Barbera-Guillem et al, 2002), pro-inflammatory cytokines and
enzymes (Kataki et al, 2002; Blot et al, 2003). A recent in vivo study
by Wyckoff et al demonstrated a synergistic relationship between
breast tumour cells and macrophages in cell migration and
suggested a role for tumour associated macrophages in metastasis
(Wyckoff et al, 2004). In addition clinical studies in breast
and endometrial cancer have reported positive correlations
with angiogenesis and/or survival (Leek et al, 1996; Salvesen
and Akslen, 1999). However, the precise role of monocytes and
macrophages in tumour angiogenesis and the growth of solid
tumours is as yet unclear.
In the current study human monocytes isolated from peripheral
blood were cocultured with human breast T47D tumour spheroids
allowing monocyte migration into the tumour spheroid where
differentiation into tumour-associated macrophages occurs (Konur
et al, 1998). A necrotic core developed in the breast tumour
cell spheroids presumably due to the hypoxic central regions, with
HIF1a staining evident surrounding the necrosis. This was similar
both in the presence and absence of macrophages and therefore is
unlikely to be due to a direct anti-tumour action of the
macrophages. VEGF is a potent endothelial cell mitogen and has
previously been shown to be released from both T47D tumour cells
and macrophages (Blancher et al, 2000) Breast tumour spheroids
containing macrophages demonstrated elevated VEGF release
(determined by ELISA) when compared to spheroids cultured in
the absence of macrophages. In addition a second angiogenesis
factor bFGF was measured, using an ELISA, but release of this
mitogen was not detected. This data is in agreement with previous
studies demonstrating that T47D human breast tumour spheroids/
cells do not release bFGF (Luqmani et al, 1992) The aim of the
current study was to identify whether tumour associated macro-
phages are involved in the initiation of angiogenesis. Thus the
spheroids required coating to allow diffusion of angiogenic factors
out of the spheroids but prevent spheroid infiltration of
autologous murine macrophages. A number of studies have used
alginate, derived from brown seaweed, as a means of encapsulating
cells for in vivo implantation, thereby isolating them from the host
immune cells. Previous studies demonstrated the coating has no
effect on cellular growth or proliferation, and indicated that in the
first week after implantation in vivo, mononuclear cells migrated
to the rim of the alginate spheroid but there was no penetration,
and over the following nine weeks, the number of migrating cells
gradually decreased (Read et al, 1999, 2001). The permeability to
diffusible molecules was demonstrated by Hoescht staining of
tumour cells, following addition to the culture medium, and the
release of VEGF but not cells into the well suggesting that coating
allowed the passage of molecules but not cells into and out of the
spheroids. Immediately before implantation a sample of spheroids
was collected, and processed for histology and immunohistochem-
istry, which demonstrated the viability of both tumour cells and
macrophages, surrounding the hypoxic centre. The number of
macrophages present in breast tumour samples has rarely been
documented, the majority of published studies relating tumour
Day 3 Day 7
0
10
20
30
macrophages
No macrophages
Day 3 Day 7
0
50
100
150
Vessel length
Day 3 Day 7
0
25
50
75
Number of vessels
Number of junctions
Figure 3 Angiogenesis was assessed off-line from video recordings taken
three and seven days after implantation of alginate coated breast tumour
spheroids. The image analysis package Angiosys, UK was used to quantify
vessel length, the number of vessels and the number of junctions
surrounding spheroids with and without macrophage at days 3 and 7 after
implantation. (n¼ 5 mean7s.e.m.). * Denotes Po0.01(vessel number,
day3), 0.008 (vessel length day 3), 0.025 (number of junctions day 3), 0.021
(vessel length day 7) when compared to no macrophage group using
Mann–Whitney U Test.
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associated macrophages with tumour survival focus on macro-
phage ‘‘hot spots’’ and their relationship to markers of angio-
genesis in tumour sections. A recent study by Bouma-ter Steege
et al (2004) did, however, calculate the relative levels of leukocytes
within breast tumour biopsies and found 490 macrophages/mm2 in
medullary carcinomas and 343 mm2 in ductal carcinomas.
The role of macrophages has not been extensively studied in
vivo. The hypothesis of the current study is that the presence of
macrophages increase the angiogenic potential of tumour spher-
oids through the increased production of VEGF. Thus to evaluate
any role for macrophages in the initiation of tumour angiogenesis,
an in vivo model involving the implantation of breast tumour
spheroids into a dorsal skinfold chamber on nude mice has
been developed in our laboratory. The mice are immunodeficient,
with an absence of T cells but a normal complement of B cells
and elevated levels of both natural killer cells and macro-
phages. Macrophages in nude mice appear more potent than
those from mice with a normal thymus (Budzynski and
Radzikowski, 1994).
Following implantation, parameters measured to determine any
effect of the macrophages on angiogenesis included vessel length,
vessel numbers, junctions or branch points, in areas directly
adjacent to, in addition to distant from the spheroid. Mean vessel
diameter is not presented as often distant sites included large host
vessels present throughout the procedure, which skewed analysis.
The angiogenesis parameter measurements three days after
implantation of the tumour spheroid indicated that macrophages
play a role in the initial angiogenic response, with significant
increases in the density of blood vessels and the number of
junctions, with a reduction in vessel length in comparison to
control spheroids composed solely of tumour cells. The shorter
vessel length was an unexpected and as yet unexplained finding
although vessels were generally of a length found in other in vivo
models (Donovan et al, 2001). Tumour cells are a known source of
angiogenic factors and T47D tumour cells produce VEGF, thus it
was not surprising that over the course of the experiment, the
tumour spheroids without human macrophages showed evidence
of increased angiogenic activity surrounding the spheroids. By day
7 there were no significant differences in the angiogenic
parameters measured between the experimental and control
groups, although immunohistochemistry demonstrated that the
macrophages continued to release VEGF. At the end of each
experiment all tissue from the chamber was processed and stained,
and demonstrated that the tumour cells remained viable, that
macrophages remained within the spheroid throughout the
experimental period and that host macrophages had not per-
meated the alginate coating. The size of each spheroid was not
measured at the end of the experiments, but previous studies have
shown that it is possible for cell growth to occur within the
confines of the agarose coating (Read et al, 1999, 2001).
In conclusion therefore, the current study demonstrates that
macrophages present within a solid tumour may significantly
contribute to the initiation of angiogenesis. However, in the
absence of macrophages, tumour cells produce the necessary
stimuli to initiate tumour angiogenesis but initiation is delayed.
Further long-term studies, using a syngenic murine model and
uncoated spheroids infiltrated with host murine macrophages,
allowing the tumour stroma to play a role, or with host
macrophage function inhibited, would allow the contribution of
macrophages to the maintenance of angiogenesis, endothelial cell
survival and tumour growth to be determined. In addition the
model could be used to assess the future of the macrophage as a
target for tumour therapy.
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